New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 18, 2014
08:03 EDTNVOXencor and Novo Nordisk partner for novel drug development
Subscribe for More Information
08:03 EDTPFEPfizer reports statistically significant results in Phase 3 pregabalin study
Pfizer announced top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release formulation in adult patients with postherpetic neuralgia. The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response in pain reduction. PHN is a type of peripheral neuropathic pain caused by nerve damage. Symptoms include continued burning or electric shock-like pain.1 This study is the final of three Phase 3 studies of the pregabalin CR formulation conducted to ascertain the potential use of pregabalin as a once-a-day therapy. The first study in adults with partial onset seizures with epilepsy did not meet its primary endpoint. In the second study in patients with fibromyalgia, pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to LTR in pain reduction. The objective of the Phase 3 double-blind, randomized, placebo-controlled study was to evaluate the safety and efficacy of pregabalin CR compared with placebo in the durability of effect for the treatment of pain associated with PHN among patients who initially respond to single-blind pregabalin.
07:36 EDTMRKMerck acquires OncoEthix, terms include upfront payment of up to $110M
Subscribe for More Information
07:28 EDTPFEPfizer shares poised to perform well in 2015, says Deutsche Bank
Subscribe for More Information
06:27 EDTAMGNAmgen's new leukemia drug to cost $178,000, Reuters reports
Subscribe for More Information
December 17, 2014
17:47 EDTAMGNAmgen raises Q1 dividend 30% to 79c per share
Subscribe for More Information
11:28 EDTSHPGNPS Pharmaceuticals calls active on Shire considering bid report
Subscribe for More Information
11:13 EDTSHPGShire considering bid for NPS Pharmaceuticals, Bloomberg reports
Subscribe for More Information
10:53 EDTAGNAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
10:49 EDTSHPGNPS Pharmaceuticals jumps 12%, halted after report of potential Shire bid
Shire (SHPG) has NPS Pharmaceuticals (NPSP) on the top of its list of potential takeover targets, but is also said to be considering other targets, according to Bloomberg.
10:47 EDTSHPGNPS Pharmaceuticals said to be on top of Shire takeover list, Bloommberg says
Subscribe for More Information
10:47 EDTSHPGNPS halted for volatility after Bloomberg says Shire considers bid
Subscribe for More Information
10:36 EDTMRKCowen pharmaceuticals analysts hold an analyst/industry conference call
Analyst Research Team discusses the imminent Merck/Cubist Zerbaxa opportunity and the Cempra SOLITAIRE-ORAL Trial readout on an Analyst/Industry conference call to be held on December 17 at 2 pm.
10:02 EDTAGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:04 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
08:06 EDTJNJInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information
08:01 EDTPFEPfizer initiates Phase 2 PF-06252616 study
Subscribe for More Information
06:28 EDTAGNAllergan downgraded to Neutral from Buy at UBS
UBS downgraded Allergan (AGN) to reflect acquisition by Actavis (ACT).
December 16, 2014
09:28 EDTAGNAllergan to host special shareholder meeting
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use